Objective To explore the clinical efficacy of Yuquan capsule combined with dapagliflozin in the treatment of type 2 diabetes mellitus(T2 DM). Methods Totally 128 patients with T2 DM in the hospital were selected from September 2022 to September 2023, and were randomly divided into single drug treatment group (n=64, dapagliflozin) and combined drug treatment group(n=64, Yuquan capsule + dapagliflozin). The clinical efficacy, TCM symptoms scores, serum neutrophil to lymphocyte ratio(NLR) and monocyte to high-density lipoprotein ratio(MHR) before and after treatment, blood glucose status before and after treatment and occurrence of adverse reactions were compared between groups. Results Compared with the single drug treatment group, the total effective rate of treatment was higher in the combined drug treatment group(P<0.05). After treatment, the levels of serum NLR, MHR, fasting blood glucose, 2 h postprandial blood glucose in the combined drug treatment group were lower, the insulin resistance index was smaller, and the blood glucose compliance time was shorter compared to the single drug treatment group(P<0.05). There was no significant difference in the total incidence rate of adverse reactions between both groups(P>0.05). Conclusion Yuquan capsule combined with dapagliflozin for T2DM can enhance the clinical efficacy, and reduce the levels of serum NLR, MHR and blood glucose, with safety